Search Results - "Humke, E.W."

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study by Banerjee, S., Oza, A.M., Birrer, M.J., Hamilton, E.P., Hasan, J., Leary, A., Moore, K.N., Mackowiak-Matejczyk, B., Pikiel, J., Ray-Coquard, I., Trask, P., Lin, K., Schuth, E., Vaze, A., Choi, Y., Marsters, J.C., Maslyar, D.J., Lemahieu, V., Wang, Y., Humke, E.W., Liu, J.F.

“…Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent antimitotic agent, monomethyl auristatin E, which inhibits…”
Get full text

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer by Liu, J.F., Moore, K.N., Birrer, M.J., Berlin, S., Matulonis, U.A., Infante, J.R., Wolpin, B., Poon, K.A., Firestein, R., Xu, J., Kahn, R., Wang, Y., Wood, K., Darbonne, W.C., Lackner, M.R., Kelley, S.K., Lu, X., Choi, Y.J., Maslyar, D., Humke, E.W., Burris, H.A.

“…MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody–drug conjugate (ADC), DMUC5754A, contains the…”
Get full text